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Abstract
Epidemiological studies have shown that
Asian populations display a lower incidence of
hormone-dependant cancers, cardiovascular
disease, osteoporosis, and menopausal ailments
compared to Western societies. Available data
support the proposal that lower incidence is
associated with the high dietary consumption
of isoflavones, such as genistein. This study
used two-dimensional electrophoresis to char-
acterize the effect of genistein on the proteome
of an endometrial tumor cell model, namely the
Ishikawa cell line. Proteome maps displaying
approx 1800 proteins were obtained from cells
treated with vehicle or genistein at physiologi-
cally attainable concentrations of 0.5, 5, or 
50 µM or supra-physiological concentration,
500 µM. The effects of genistein on protein
expression were characterized using image
analysis software. A total 65 protein spots dis-
played a significant decrease in expression and
32 proteins displayed a significant increase in
expression. Of these protein spots, 29 were ran-
domly selected for characterization by matrix
assisted laser desorption/ionization tandem
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Introduction
Epidemiological studies have shown that
Asian populations display a lower incidence
of hormone-dependant cancers, cardiovascu-
lar disease, osteoporosis, and menopausal ail-
ments compared to Western societies (1,2). The
difference in incidence has been attributed to
environmental factors, predominantly diet.
This hypothesis is based upon data obtained
in studies which report that people from Asia
that migrate to a Western nation and adopt a
Western diet display similar incidence of dis-
ease as their adoptive country by the second
generation, suggesting that factors other than
genetic factors are influential (3).
Western societies typically consume diets
that are relatively high in animal fat and low
in fiber, as opposed to Asian societies, which
consume plant-based diets, rich in phytoestro-
gens. Phytoestrogens are plant-derived com-
pound with structural similarity to human
estrogenic steroids. Generally, Asian popula-
tions consume 20–50 mg of isoflavones in the
daily diet. In contrast, Western populations
ingest negligible amounts (<1 mg isoflavone)
per day (4).
Genistein, the most prominent isoflavone in
soybeans, has been extensively studied as a
chemopreventive or therapeutic agent in sev-
eral forms of cancer (5). Over the past decade,
many studies have focused on elucidating
which, if any, cellular mechanisms are regu-
lated by genistein that may lead to protection
from cancer. In vitro studies have demon-
strated that genistein displays biphasic effects
on cancer cell growth, stimulating growth at
low concentrations (<10 µM) and inhibiting
growth at higher concentrations (>10 µM) (6).
It binds to both estrogen receptor α and β and
elicits a weak estrogenic response. Further-
more, genistein acts as a protein tyrosine
kinase inhibitor, and is able to block the cell
cycle in the G2/M transition, inhibit Akt
kinase, topiosomerase II, and cAMP-phospho-
diesterase-4 enzymes (7–12).
Studies to date have typically focused on
specific candidate pathways previously asso-
ciated with cancer. By focusing on the regula-
tion of such pathways, other putative effects
of genistein on cellular function remain to be
elucidated. Changes to the cellular proteome
elucidated by phytoestrogens have also been
reported, however these studies are, to date,
limited (13–16). Recently, several studies have
reported the use of two-dimensional elec-
trophoresis (2D-PAGE) technology to identify
proteome changed elucidated by genistein
(13,15–17).
In this study, 2D-PAGE technology was
used to characterise changes in the proteome
elicited in an endometrial carcinoma cell line,
Ishikawa, treated with previously reported
physiologically attainable genistein concentra-
tions, 0.5, 5, and 50 µM (18–22) and the supra-
physiological concentration, 500 µM compared
to vehicle treated cells. This type of analysis
was employed as it enabled the characteriza-
tion of a wider range of cellular proteins and
possible biochemical pathways that may be
regulated or affected by genistein. It is a pow-
erful and widely used method for the analy-
sis of complex protein mixtures extracted from
cells (23–25).
mass spectrometry, yielding 18 different pro-
teins. This type of analysis enabled the charac-
terization of a wide range of cellular proteins
and allowed for the identification of functional
and biochemical pathways that may be regu-
lated or affected by genistein, including cellular
transcription, cell proliferation, stress response,
or modulation of oncogenic pathways.
05_Konstantakopoulos  10/19/07  7:47 AM  Page 154
Volume 2, 2007 ________________________________________________________________ Clinical Proteomics
Genistein and Endometrial Cancer ____________________________________________________________ 155
Materials and Methods
Cells and Chemicals
The estrogen receptor α- and β-positive
endometrial carcinoma cell line, Ishikawa, was
kindly provided by Dr. H. Sokamoto (26)
(Nihon University, Tokyo, Japan). The follow-
ing reagents were purchased from Sigma 
(St. Louis, MO); CHAPS, α-cyano-4-hydrox-
ycinnamic acid, genistein (4’,5,7- trihydroxy-
isoflavone), Hanks’ balanced salt solution
(Hanks), MgCl2, phenylmethanesulfonyl fluo-
ride, sodium dodecyl sulfate (SDS), thiourea,
and tributylphosphine. Eagle’s minimal
medium without phenol red was purchased
from Gibco BRL (Auckland, New Zealand).
Fetal bovine serum (FBS) was purchased from
CSL (Melbourne, Australia). Penicillin/strep-
tomycin and trypsin was purchased from
Trace Scientific (Melbourne, Australia). Ace-
tonitrile, dimethyl sulphoxide (DMSO), formic
acid, methanol, orthophosphoric acid, and
Tris-HCl were purchased from Merck (Darm-
stadt, Germany). The Coomassie protein assay
kit was purchased from Pierce (Rockford, IL).
Coomassie R-250 and Coomassie G-250,
deoxyribonuclease, glycine, and ribodeoxynu-
clease were purchased from ICN Pharma-
ceuticals (Costa Mesa, CA). Agarose M,
bromophenol blue, dithiothreitol, IPG buffer
3–10 L, IPG polyacrylamide linear pI 3–10
strips were all purchased from GE Healthcare
(Uppsala, Sweden). Modified trypsin was
from Promega (Madison, WI). Gel loader tips
were from Eppendorf (Hamburg, Germany).
Poros R2 material was from Applied Biosys-
tems (Framingham, MA). Broad range molec-
ular weight markers and electrophoresis wicks
and SYPRO Ruby gel stain were purchased
from Bio-Rad Laboratories (Hercules, CA).
Cell Culture and Genistein Treatment
Ishikawa cells were cultured in 10 mL
Eagle’s minimal medium without phenol red,
supplemented with 10% charcoal-treated FBS
and 1% penicillin/streptomycin, in 25-cm2
flasks until 80% confluent. Cells were washed
three times using prewarmed Hanks solution,
pH 7.2, and incubated for a further 24 h in 
10 mL of culture medium, without charcoal-
treated FBS, at 37°C in 5% CO2 in the presence
of 0.5, 5, 50, or 500 µM genistein or with vehicle
alone (DMSO:methanol). All treatment groups
had a final concentration of 0.5% v/v DMSO:
methanol. The cells were washed three times
with prewarmed Hanks, and then lysed using a
solution comprising 6 M urea, 2 M thiourea, 4%
CHAPS, and 4.5 mM phenylmethanesulfonyl
fluoride. Cells were incubated at room temper-
ature for 30 min and the lysate was collected
and stored at –80°C.
DNase/RNase Treatment
Protein lysates were treated with DNase and
RNase (0.1 vol of 1 mg/mL DNase and 25
mg/mL RNase diluted in 50 mM MgCl2). Sam-
ples were incubated at room temp for 30 min,
and centrifuged at 16,100g for 20 min. Super-
natant was removed and stored at –80°C.
Protein Assay
Total protein determination was performed
using a Coomassie protein assay kit, following
the manufacturer’s instructions.
Two-Dimensional Electrophoresis
2D-PAGE, IEF in the first dimension and
SDS-PAGE in the second dimension, was per-
formed as described by Gorg et al. with minor
modifications (27). Briefly, Immobiline IPG
strips were actively rehydrated in 350 µL rehy-
dration solution (150 µg protein, 8 M urea, 2%
CHAPS, 2% IPG buffer 3–10 L, 18 mM dithio-
threitol, bromophenol blue) at 50 V for 850 Vh
using a GE Healthcare IPGPhor system. Wicks
were placed under the electrodes and the IEF
was performed at 500 V for 30 min, 1500 V for
1 h and 8000 V for 3 h until approx 24,000 Vh
were reached. Strips were equilibrated for 
15 min in SDS equilibration buffer (6 M Urea,
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50 mM Tris-HCl pH 8.8, 30% glycerol, 2% SDS,
2 mM tributylphosphine, bromophenol blue)
then soaked in SDS electrophoresis buffer 
(25 mM Tris, 192 mM glycine, 0.1% SDS) and
placed on top of a 1-mm thick 12% homo-
genous polyacrylamide gels (prepared accord-
ing to Hoefer Dalt manual). Molecular weight
markers were placed on a filter paper and
inserted next to the strip. Strips were then
sealed using agarose sealing solution (100 mL
SDS electrophoresis buffer, 0.5% agarose M,
bromophenol blue). Gels were run using a
Hoefer Dalt system (GE Healthcare) at 100 V at
10°C for 17 h in SDS electrophoresis buffer or
until the dye front ran off the gel.
Protein Detection
Proteins were visualized using SYPRO
Ruby fluorescent dye. Gels were stained for 3 h
according to the manufacturer’s instructions.
Images were captured using a FX Pro Plus
Imager (Bio-Rad Laboratories).
Quantification of Proteins
PD Quest, v6.2.1 (Bio-Rad Laboratories) was
used for protein spot analysis. Initially, protein
spots were matched automatically, and remain-
ing proteins were manually matched as appro-
priate. Gels were normalized according to the
total protein in the gel.
Statistical Analysis
Background values were subtracted from
each gel and the spot volume in each gel was
calculated. Statistical analysis was performed
using PD Quest v6.2.1. Gels of the same treat-
ment were grouped together to form replicate
groups. Differences between groups (that is,
genistein treatment vs control) were calculated
using Mann-Whitney U-test, where p < 0.05
was regarded as significant.
Excising Protein Spots
Gels were stained in colloidal Coomassie
(17% ammonium sulfate, 3% orthophosphoric
acid, 0.1% Coomassie G-250, 34% methanol).
After rocking for 4 h at room temperature, gels
were placed in 30% methanol and rocked to
destain until spots could be seen clearly (approx
2 h). Spots of interest were identified by eye,
excised manually using a scalpel and placed in
microcentrifuge tubes for further analysis.
In-Gel Digestion
In-gel digestion was performed as previ-
ously described (28). The supernatant from the
digestion was either analyzed directly by
matrix assisted laser desorption/ionization
tandem mass spectrometry (MALDI-TOF/
TOF) described in section MALDI-TOF/TOF
protein identification, or an aliquot of the
supernatant was desalted and concentrated
using microcolumns prior to MALDI-TOF, as
described next.
Desalting and Concentration of Peptide
Mixtures
Desalting and concentration of the peptide
mixtures prior to mass spectrometric analysis
was performed in custom-made microcolumns
containing 100–300 n/L of Poros R2 material
(Applied Biosystems, 20 µm bead size) packed
into a constricted GeLoader pipet tip as
described previously (29,30). A 10-mL syringe
was used to force liquid through the column
by applying gentle air pressure. Peptide mix-
tures were dissolved in 5% formic acid, loaded
onto the column, and washed with 20 µL of
5% formic acid. For analyses by MALDI TOF,
peptides were eluted with 0.4 µL matrix solu-
tion (15–20 g/L of α-cyano-4-hydroxycinnamic
acid in 70% acetonitrile/0.1% TFA) and
deposited in very small droplets directly onto
the MALDI target.
MALDI-TOF/TOF Protein Identification
MALDI tandem mass spectrometry was
performed using a ABI 4700 Proteomics Ana-
lyzer (Applied Biosystems) with TOF/TOF
optics, equipped with a Nd:YAG 200 Hz laser.
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Spectra were obtained by accumulation of
1500–3000 consecutive laser shots. All spectra
were obtained in positive reflector mode. Air
was used as collision gas for collision-induced
dissociation. One MS spectrum covering the
mass range 700 to 4000 Da was obtained for
each peptide solution. A total of seven colli-
sion-induced dissociation fragment ion spec-
tra of the seven highest abundant peptides
from each MS spectrum were obtained.
The proteins were identified based on the
MALDI tandem MS data using the database
search program GPS Explorer Workstation,
employing an in-house MASCOT server (v1.8)
with p < 0.01 (Matrix Sciences, London, UK)
(31). The search was performed on both MS
and MS/MS data simultaneously. The peptide
mass maps and protein identifications were
evaluated as previously described (32).
Results
All genistein treatments were preformed in
quadruplicate. Protein content of cells follow-
ing treatment with 0.5, 5, 50 µM genistein or
control was approx 1.7 mg/mL (SEM: 0.070),
however, upon treatment with 500 µM genis-
tein the protein concentration decreased to
approx 0.9 mg/mL (SEM: 0.092). Proteins (150
µg) were separated using 2D–PAGE. Figure 1
shows a representative display of Ishikawa
cell lysate focused in first dimension on an 
18-cm polyacrylamide gel strip between linear
Fig. 1. Representative example of SYPRO Ruby stained 2D-PAGE gel of proteins obtained from vehicle-treated
Ishikawa cells and separated using linear pH 3.0–10.0 polyacrylamide strips in the first dimension and 12%
homogenous gel in the second dimension.
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pI of 3–10 and run on 12% SDS-PAGE gel. All
gels displayed approx 1800 protein spots. The
spots were separated between the pH range
3.0 and 10.0 and Mr 15 to 100 kDa, however,
the majority of proteins appeared between the
pH range 4.0 and 7.0 with Mr between 25 and
70 kDa.
Treatment with genistein at physiological
concentrations of 0.5, 5, and 50 µM resulted 
in significant increase in expression in 32
proteins (p < 0.05) and significantly decreased
expression in 45 proteins (p < 0.05). At the
supra-physiological concentration of 500 µM, 
a total of 20 proteins displayed a significant
decrease in expression (p < 0.05) (refer to
Table 1).
A total of 29 gel spots that displayed signif-
icant differences in expression levels in control
vs treatment were chosen at random from the
various genistein treatments, gel plugs excised
and proteins identified by MALDI TOF/TOF
MS. To determine if PD Quest matched protein
spots accurately, a matched spot was excised
from gels with genistein treatments 5, 50, and
500 µM and characterized, all spots were iden-
tified to be TCP1 protein. Three of the excised
proteins were found to consist of two unre-
solved proteins. Seven spots remained uniden-
tified, four of which did not contain a match
in the database, whereas three were of very
low abundance and unable to be characterized.
Proteins that displayed significant differential
expression (p < 0.05) following genistein treat-
ment, identified using MALDI TOF/TOF MS
are listed in Table 2. Changes in protein
expression levels at all other genistein concen-
trations are also included in Table 2.
The proteins identified in all treatment con-
centrations are associated with cellular tran-
scription, cell proliferation, stress response, or
modulation of oncogenic pathways.
Discussion
Genistein has been widely studied over the
past decade to identify putative chemopre-
ventative properties. Various biological signal
transduction pathways associated with the
development of cancer, including nuclear
factor (NF)-κB, AKT, and MEKK are regulated
by genistein (8,33,34). This study used 
2D-PAGE and tandem mass spectrometry to
perform proteomic analysis on the endome-
trial carcinoma cell line, Ishikawa, treated with
previously reported physiologically attainable
genistein concentrations, 0.5, 5, and 50 µM
(18–22) and the supra-physiological concen-
tration, 500 µM. This study enabled the direct
measurement of proteins in terms of their
presence and relative abundance.
2D-PAGE gels typically contained approx
1800 protein spots, with the majority appear-
ing between pH range 4.0 and 7.0 and Mr of
25 to 70 kDa. A total of 97 proteins displayed
significant differential expression following
genistein treatment at various concentrations,
with 65 protein spots displaying a significant
decrease in expression, and 32 protein spots
identified as showing a significant increase in
Table 1
Number of Proteins Significantly Up- or Downregulated in Ishikawa Cellsa





aFollowing genistein treatment with physiological concentrations, 0.5, 5, and 50 µM or supra-physiological
concentration, 500 µM (p < 0.05).
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expression. Of these spots, 29 were randomly
selected and excised from the gel to be char-
acterized, from which 18 different proteins
were unequivocally identified.
This study demonstrated that treatment
with physiologically achievable or supra-
physiological concentrations of genistein,
regulated five proteins, PCBP2, FUSE, hnRNP
C, hnRNP M, and hnRNP H2, involved in
modulating the expression of c-myc. Temporal 
c-Myc protein accumulation is essential for
normal cell proliferation. It also plays a key
role in cellular differentiation, apoptosis and
cell cycle. C-myc is also an oncogene and over
expression of Myc protein is known to lead to
neoplastic progression, whereas depletion
results in inhibition of DNA splicing and sub-
sequently translation of proteins (35–38).
There are several reports showing elevated 
c-myc gene and protein expression or ampli-
fication in premalignant and/or malignant
lesions of the endometrium, with increased
levels correlating to poor prognosis (39–42).
The expression of FUSE binding protein
was downregulated following treatment with
5 or 50 µM genistein. This protein binds to
active c-myc genes and is necessary for c-myc
expression. Two members of the hnRNP
family, hnRNP C and hnRNP H2 were also
downregulated by 0.5 or 5 µM genistein and
5, 50, or 500 µM genistein respectively,
whereas another member, hnRNP M was
downregulated following treatment at the
supra-physiological genistein concentration of
500 µM. These proteins are part of the RNA
splicesome and function to modulate transla-
tion at the G2/M phase (43). hnRNP C has
been shown to enhance translation of c-myc
mRNA (43). Using 2D-PAGE technology, ele-
vated levels of human hnRNP A2/B1 in
endometrial adenocarcinoma cells, as well as a
significant increase in hnRNP F in Ishikawa
cells treated with estrogen have been demon-
strated (44,45). Using cDNA microarray analy-
sis we previously observed decreased gene
expression of six members of the hnRNP
family following treatment of Ishikawa cells
with 50 µM genistein (unpublished results).
Treatment with 50 or 500 µM genistein down-
regulated the expression of PCBP2, with 500
µM genistein downregulating expression by
more than 10-fold. c-Myc contains internal
ribosomal entry sites (IRES) and PCBP2 facili-
tates in translation of reported RNAs contain-
ing IRES. Interaction between PCBP2 and
c-myc-IRES-RNA has been demonstrated to
result in a threefold increases in activation of
IRES (46). Diminishing levels of this protein
leads to significantly decreased ability to trans-
late such RNA, thus resulting in decreased
levels of protein expression. Previous studies
have shown genistein’s ability to decrease c-
Myc protein in vivo (47). Furthermore, genis-
tein has also been shown to suppress c-myc
mRNA expression in vitro (48,49).
GTP binding protein was downregulated
following treatment with 5 or 50 µM genistein
confirming our cDNA microarray analysis,
where a decrease in gene expression of GTP-
binding protein following 5 µM genistein
treatment was observed (50). Decreased gene
expression was also seen with 50 µM genistein
treatment (unpublished results). This protein
has been implicated in the Ras-related signal
transduction pathway. Rho GDP dissociation
inhibitor, an inhibitor of the Rho pathway, and
a modulator of GTPase was also downregu-
lated following treatment with 5 or 50 µM
genistein. Rho GTPases are prominent partici-
pants in malignant transformation and are
regulated by the Ras pathway (51,52).
c-Myc protein is stabilized by activation of
Ras through multiple effector pathways (53).
Proteins of the Ras pathway represent a fun-
damental component in the control of cellular
responses, such as proliferation, differentia-
tion, cell cycle control, gene expression, actin
cytoskeleton control and intracellular traffic,
and nucleocytoplasmic transport, to many
incoming signals and in particular mitogenic
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stimuli (54,55). All of these proteins are able to
bind to GTP and GDP and exhibit slow
GTPase activity (56). Ras is also described as a
prominent participant in malignant transfor-
mation and is commonly mutated or ampli-
fied in endometrial cancer (52,57). Inhibition
of Ras activation, or inhibition of proteins
facilitating the expression or function of the
oncogene c-myc, could inhibit the progression
of oncogenesis.
Genistein treatment with physiologically
achievable or supra-physiological concentra-
tions, regulated five chaperone proteins.
Chaperone and heat shock proteins play
important roles in tumor biology (58).
HSC70, a molecular chaperone involved in
protein folding, was upregulated by treatment
with 5 or 50 µM genistein. The molecular
chaperone activity may contribute to tumoro-
genesis, by providing the cancer cell with an
opportunity to alter protein activities, in par-
ticular components of the cell cycle machinery,
kinases and other proteins implicated in
tumor progression (58). The expression of this
protein is increased in response to heat, oxida-
tive stress, and hypoxia. Cells with low levels
usually undergo apoptosis (59,60). Increased
levels of HSC70 have been reported in 31
cancer cell lines, including Ishikawa, com-
pared to noncancerous control cell lines (61).
HSC70 protein was also expressed in high
abundance in 10 tumor cell lines (58). Further-
more, studies raise the possibility that HSC70
may be directly involved in the modulation of
oncogene-mediated transformation (62).
A member of the small heat shock proteins,
HSP27 protein 1, was downregulated by phys-
iological concentration of 0.5 or 5 µM, as well
HSP27 was downregulated by supra-physiolo-
gical concentration, 500 µM genistein. This 
protein regulates epithelial cell growth and dif-
ferentiation, wound healing, apoptosis, and cell
protection against inflammatory cytotoxicity
mediators. Elevated levels inhibit necrotic and
apoptotic cell death and have been noted in
proliferative epithelial breast cancer cells com-
pared to normal (63–66). Patients with endo-
metrial breast or ovarian cancer, expressed
increased levels of antibodies against HSP27
compared to women with benign tumours,
strongly suggesting the presence and increased
levels of HSP 27 in their circulation (67,68). Fur-
thermore, HSP27 expression has previously
been reported to be elevated in endometrial
adenocarcinoma cells (44).
Chaperone protein ERp29 was downregu-
lated by treatment with 5, 50, or 500 µM genis-
tein. ERp29 shares high sequence similarity to
the protein disulfide isomerase family and is
described as playing an important role in pro-
cessing of secretory proteins within the endo-
plasmic reticulum and a ubiquitously present
(69,70). ERp29 has previously been displayed
to be present in high abundance in five tumor
cell lines (58). Calreticulin, a chaperone for
glycoproteins in the endoplasmic reticulum,
was upregulated following treatment with 5
or 50 µM genistein, however, treatment with
0.5 µM genistein downregulated expression.
This protein also belongs to the protein disul-
fide isomerase family and may inhibit angio-
genesis, suppresses tumor growth and inhibit
endothelial cell proliferation (69,71–75).
Incubation of Ishikawa cells with 5, 50, or
500 µM genistein downregulated the expres-
sion of TCP1 protein subunits. Using cDNA
microarray analysis, we previously observed
a decrease in TCP1 gene expression following
treatment of Ishikawa cells with 50 µM genis-
tein (unpublished results). TCP1 proteins are
heat shock proteins belonging to stress protein
family. They are required for the folding of
tubulins, actins as well as other cytosolic pro-
teins, to attain microfilament assembly, hence
assisting in cell growth (76,77). The expression
levels of TCP1 is closely correlated with
growth rates of mammalian cultured cells,
with expression strongly upregulated during
growth from G(1)/S transition to early S phase
(78,79). Tumor tissues have shown significantly
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higher levels of TCP1 expression, as opposed
to nontumor tissue and because it is widely
distributed in the cytosol, it may represent a
useful tumor marker. A high abundance of
TCP1 has also been displayed in 10 tumor cell
lines (58).
The regulation of genes involved in cell
cycle, DNA replication, DNA repair, and
mitosis involves the function of many pro-
teins, including E2F, UDG, and prohibitin.
Using cDNA microarray analysis we previ-
ously demonstrated decreased gene expres-
sion of E2F and UGD following treatment
with 50 µM genistein (unpublished results). In
this study, E2F protein expression was down-
regulated following treatment with 5 or 500
µM genistein. This protein displays RNA
polymerase II transcription factor activity
with positive regulation of cell cycle activity
and has been shown to be associated with
several Ras proteins (80). UDG protein was
also downregulated following treatment with
5 or 500 µM genistein. UDG is activated by
E2F-1 and removes the uracil moieties from
DNA and functions to repair U:G mispairs
(81). Prohibitin, was downregulated following
treatment with 500 µM genistein. Prohibitin is
a proto-oncogene involved in cell-cycle con-
trol and senescence, is known to suppress
growth and repress E2F mediated transcrip-
tion, inhibiting apoptosis and has been shown
to be elevated in endometrial adenocarcinoma
cells (44,82,83).
Enolase 1 protein was downregulated fol-
lowing treatment with 500 µM genistein.
Using cDNA microarray analysis, we previ-
ously observed a decrease in gene expression
of enolase 1 following treatment of Ishikawa
cells with 50 µM genistein (unpublished
results). This protein is involved in glycolysis
pathway (ADP to ATP) and has been reported
to be over expressed in 20 cancer classes (84).
Furthermore, glycolytic enzymes and alpha
enolase were also reported to be elevated in
hyperplastic and neoplastic endometrial cells,
this finding is believed to be owing to the
increase rate of glycolysis (44). Enolase 1 has
previously been described as negative regula-
tor of NF-κB (85). NF-κB is a ubiquitously
expressed, pleiotropic transcription factor,
with an important role in the control of cell
proliferation, apoptosis and oncogenesis
(86,87). Constitutively activated NF-κB has
been postulated as promoting oncogenesis in
certain cancers (87,88). Choi et al. showed that
the DNA-binding activity of NF-κB in nuclear
extracts treated with 50 and 100 µM genistein
was significantly suppressed (89).
In summary, this study used 2D-PAGE tech-
nology to display variations in protein expres-
sion of Ishikawa cells following treatment
with genistein at varying concentrations. The
findings indicate that genistein can regulate
the cellular activity of Ishikawa cells, and
hence may affect the state of the living cell.
Genistein’s involvement in either up or down-
regulating the proteins identified indicates
that it may exhibit a global effect on the cell
resulting in reduced transcription/activation
of known oncogenes or cellular proliferation,
and subsequently reduce oncogenesis. The
results obtained from this study suggest that
genistein regulates the expression of proteins
involved in endometrial oncogenesis.
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